Denderon (DNDN) Falls On Negative Research Paper
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
Shares of Denderon (Nasdaq: DNDN) are under pressure, which could be related a 27 page anonymous research paper that questions the safety of cancer drug Provenge's, which is already FDA approved. The CareToLive blog posts about the 27 page paper, calling it "bogus."
Shares of Dendreon are down 6 percent today to $31.95.
Shares of Dendreon are down 6 percent today to $31.95.
Create E-mail Alert Related Categories
Insiders' Blog, Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
